Brief: Passage Bio To Present Updated Interim Data From Imagine-1 Study For Gm1 Gangliosidosis At 19Th Annual Worldsymposium™ 2023
U.S. STOCKS ON THE MOVE-Pfizer, Harrow Health, Vallon Pharma
U.S. STOCKS ON THE MOVE-Processa Pharma, Solaredge, Immix Biopharma
U.S. STOCKS ON THE MOVE-Kymera Therapeutics, Passage Bio, Avidity
Passage Bio rises as nerve disorder therapy shows promise in study
Brief: Passage Bio Announces Positive Interim Clinical Data From First Six Patients With Gm1 Gangliosidosis In Imagine-1 Study
Passage Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Passage Bio Reports Q3 2022 Financial Results
Passage Bio Inc expected to post a loss of 79 cents a share - Earnings Preview
Passage Bio Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Passage Bio Reports Appointment Of William Chou As Chief Executive Officer
Brief: Passage Bio Doses First Patient In Global Clinical Trial Of PBFT02 Gene Therapy For Frontotemporal Dementia With Granulin Mutations
Brief: Passage Bio Q2 Loss Per Share $0.73
Brief: Passage Bio Appoints Michael Kamarck, Ph.D. To Board Of Directors
U.S. STOCKS ON THE MOVE-Grab Holdings Ltd, HeartCore Enterprises Inc, Twitter Inc
U.S. STOCKS ON THE MOVE-Omniq Corp, LumiraDx Ltd, Caterpillar Inc
Passage Bio rises on FDA nod for gene therapy trial
Brief: Passage Bio Receives FDA Clearance Of Ind Application For Pbml04 For Treatment Of Metachromatic Leukodystrophy
Brief: Passage Bio Announces Leadership Transition